Core Insights - Neurothera Labs Inc. announced that Clearmind Medicine Inc. has filed an Israeli patent application for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration between Neurothera and Clearmind aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] Company Overview - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system disorders and other underserved health conditions through collaborations [4] Intellectual Property Development - The recent patent application expands the joint intellectual property portfolio, which now includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression, alcohol use disorder, cocaine addiction, and obesity [3]